医学顶刊首发新冠临床试验结果：中国研究证实克力芝收效甚微，不能降低重症死亡率。
Results of new crown clinical trial of top issue of medical science: Chinese research has proved that Kaletra has little effect and can not reduce severe mortality.
孙滔。
Sun Tao.
DeepTech深科技                      。
Deep Technology DeepTech.
DeepTech深科技。
Deep Technology DeepTech.
DeepTech是一家关注新兴科技产业化的全链条内容、服务、数据和投融资平台，致力于构建一个全球科技创新合作网络。
DeepTech is a whole chain of content, services, data, and investment and financing platforms that focus on the industrialization of emerging technologies, and is committed to building a global science, technology, and innovation collaborative network.
。
.
3 月 19 日，《新英格兰医学杂志》（NEJM）在线发表中国团队关于抗艾滋药物洛匹那韦 / 利托那韦研究称，与常规支持治疗相比，洛匹那韦 / 利托那韦在对于新冠重症患者治疗中并未出现临床状况改善或死亡率降低。
On March 19, the New England Journal of Medicine (NEJM) published online a study by the Chinese team on the Chinese anti-AIDS drug Lopinavir / Ritonavir that showed no improvement in clinical conditions or reduced mortality in the treatment of severe cases in the new crown compared to conventional supportive treatment.
洛匹那韦 / 利托那韦即克力芝，属于 HIV - 蛋白酶抑制剂。
Lopinavir / ritonavir, or Kaletra, is an HIV-protease inhibitor.
研究显示，洛匹那韦 / 利托那韦收益甚微，仅让临床状况改善的中位时间提前了 1 天，达到 15 天，而对照组是 16 天。
Studies have shown that Lopinavir / Ritonavir yielded little benefit, bringing forward the median time for clinical improvement by only one day, to 15 days, compared with 16 days for the control group.
据《新英格兰医学杂志》称，这是疫情暴发以来，世界顶级医学杂志首次发表治疗新冠病毒的临床试验结果，也是在包括 SARS 在内的近 20 年新发传染病疫情期间发表的屈指可数的药物临床试验结果。
According to the New England Journal of Medicine, this is the first time since the outbreak that the world's leading medical journals have published the results of clinical trials for the new crown virus, and only a handful of drug clinical trials published during nearly two decades of new infectious disease outbreaks, including SARS.
论文主要作者来自中日友好医院、国家呼吸病临床研究中心以及武汉金银潭医院。
Thesis lead author comes from Sino-Japanese Friendship Hospital, National Clinical Research Center of Respiratory Disease and Wuhan Gold and Silver Pool Hospital.
通讯作者系中日医院呼吸中心曹彬、王辰以及武汉金银潭医院张定宇。
Communication authors are Cao Bin Wang Chen and Zhang Dingyu of Wuhan Gold and Silver Pool Hospital.
少有的高质量临床试验这项研究采用前瞻、随机、以标准治疗对照、开放标签的临床试验（RCT）设计。
Rare Quality Clinical Trials The study used forward-looking, randomized, standard-controlled, open-label clinical trials (RCT) designs.
该研究并非双盲，也没有限定患者从发病到入组的时间。
The study was not double-blind and did not define the time between onset and onset of the disease.
研究以 1:1 的比例将患者随机分组。
Patients were randomly grouped in a scale of 1: 1.
其中对照组 100 例患者，按照国家卫健委发布的《新型冠状病毒肺炎诊疗方案》最新版给予标准治疗；洛匹那韦 / 利托那韦组 99 例患者，在标准治疗基础上，增加洛匹那韦 / 利托那韦治疗。
In the control group, 100 patients were given standard treatment in accordance with the latest version of the New Coronavirus Pneumonia Diagnosis and Treatment Programme issued by the National Fitness and Health Commission; 99 patients in the Lopinavir / Ritonavir group received additional Lopinavir / Ritonavir treatment on the basis of standard treatment.
后者的方案是，洛匹那韦 400 毫克 / 利托那韦 100 毫克，每日 2 次，疗程 14 天。
The latter has a regimen of 400 mg / ritonavir of Lopinavir of 100 mg, twice a day for 14 days.
评价的主要终点是至临床状况改善的时间。
The main endpoint of the evaluation was the time until clinical conditions improved.
洛匹那韦 / 利托那韦组临床研究采用的是一个 7 分的复合终点指标。
The clinical study in the Lopinavir / Ritonavir group used a 7-point composite endpoint.
临床状况改善终点是世卫组织研发蓝图专家组推荐的终点。
Clinical improvement endpoints are those recommended by the WHO Expert Group on the Development Blueprint.
7 分等级量表包括以下等级：1. 未住院，且可继续从事日常活动；2. 未住院，但无法继续从事日常活动；3. 住院治疗，不需要吸氧；4. 住院治疗，需要吸氧；5. 住院治疗，需要经鼻高流量氧疗、无创机械通气或这两者；6. 住院治疗，需要 ECMO、有创机械通气或这两者均需要；7. 死亡。
The scale consists of the following grades: 1. Unhospitalized and able to continue daily activities; 2. Not hospitalized but unable to continue daily activities; 3. In-patient treatment requiring oxygen inhalation; 4. Hospitalization requiring high nasal flow oxygen therapy, non-invasive mechanical ventilation or both; 6. Hospitalization requiring ECMO, invasive mechanical ventilation or both; and 7. Death.
在被分配到洛匹那韦 / 利托那韦组的 99 例患者中，94 例（94.9%）接受了分配的治疗，5 例患者未接受洛匹那韦 / 利托那韦治疗，其中 3 例的原因是在随机分组后 24 小时内早期死亡，另外 2 例的原因是在随机分组后，主治医师拒绝开出洛匹那韦 / 利托那韦。
Of the 99 patients assigned to the Lopinavir / Ritonavir group, 94 cases (94.9 per cent) received the prescribed treatment, 5 patients did not receive Lopinavir / Ritonavir treatment, 3 cases resulted from early death within 24 hours of randomized grouping, and 2 cases were due to the refusal of the attending physician to prescribe Lopinavir / Ritonavir after randomized grouping.
图 | 意向治疗人群中至临床状况改善的时间：横轴为有风险的人数，纵轴为累积改善率。
Number of people at risk on the horizontal axis and cumulative improvement rate at the longitudinal axis.
（来源：新英格兰医学杂志）研究发现，对于新冠重症患者，与常规支持治疗相比，洛匹那韦 / 利托那韦组并未出现临床状况改善或死亡率降低。
(Source: New England Journal of Medicine) The New England Journal of Medicine found no clinical improvement or mortality reduction in the Lopinavir / Ritonavir group compared with routine supportive care.
在排除了 3 例早期死亡患者的改良意向治疗分析中，两组间至临床状况改善的中位时间为洛匹那韦 / 利托那韦组 15 天，而对照组为 16 天。
In the modified intention treatment analysis, which excluded 3 cases of early death, the median time for improvement in clinical status between the two groups was 15 days for the Lopinavir / Litonavir group and 16 days for the control group.
研究认为尽管差异很小但达到了统计学显著性。
The study found that the difference was small but statistically significant.
其中与单独采用常规支持治疗相比，研究并未发现加用洛匹那韦 / 利托那韦可降低病毒 RNA 载量或缩短检出病毒 RNA 的时间。
Among them, the study did not find that adding Lopinavir / Ritonavir could decrease viral RNA load or shorten the time it took to detect viral RNA, compared with routine supportive treatment alone.
至于安全性，共有 51 例患者发生了严重不良事件：洛匹那韦 / 利托那韦组 19 起和对照 32 起。
As for safety, a total of 51 patients had serious adverse events: 19 in the Lopinavir / Litonavir group and 32 in the control group.
洛匹那韦 / 利托那韦组发生了 4 起胃肠道严重不良事件，而对照未发生胃肠道严重不良事件；研究者判定这 4 起事件均与试验药物相关。
Four severe adverse gastrointestinal events occurred in the Lopinavir / Litonavir group, compared with no significant adverse events in the gastrointestinal tract; the researchers determined that all four incidents were related to the test drug.
对照患者的呼吸衰竭、急性肾损伤和继发感染发生率高于洛匹那韦 / 利托那韦组。
The incidence of respiratory failure, acute renal injury and secondary infection was higher in the control group than in the Lopinavir / Ritonavir group.
接受洛匹那韦 / 利托那韦治疗的患者中有 13 例（近 14%）无法完成 14 天的完整疗程，主要原因是厌食、恶心、腹部不适或腹泻等胃肠道不良事件和两起严重不良事件（均为急性胃炎）。
Thirteen patients (nearly 14 per cent) who received Lopinavir / Ritonavir were unable to complete the full 14-day course, mainly due to adverse gastrointestinal events such as anorexia, nausea, abdominal discomfort or diarrhoea, and two severe adverse events (both acute gastritis).
世卫组织高度关注的研究据曹彬介绍，洛匹那韦 / 利托那韦被世界卫生组织列为应对新冠病毒全球研发蓝图计划的亟待评价药物之一。
Lopinavir / Ritonavir is listed by the World Health Organization as one of the drugs to be evaluated as part of a global blueprint for research and development to tackle the new crown virus, according to Cao Bin.
世界卫生组织高度关注研究进展，并多次致电曹彬询问研究主要结果。
WHO paid close attention to the research progress and called Cao Bin several times to inquire about the main results.
国家卫健委科教司组织专家评审，高度肯定了本次临床试验的意义，认为本研究为新冠重症临床救治提供了直接依据。
The scientific and educational department of the National Health Council organized expert review, highly affirmed the significance of this clinical trial, the study provides a direct basis for the new crown severe clinical treatment.
此前研究发现，洛匹那韦对引起人类 SARS 病毒具有体外抑制活性，而利托那韦与洛匹那韦联用可通过抑制细胞色素 P450 来延长洛匹那韦的血浆半衰期。
Previous studies have found that lopinavir has an in vitro inhibitory activity to cause human SARS virus, while Ritonavir, in combination with Lopinavir, can extend the plasma half-life of Lopinavir by inhibiting cytochrome P450.
2004 年发表的一项开放标签研究提示，利巴韦林加用洛匹那韦 / 利托那韦，降低了 SARS 患者的不良临床结局风险和病毒载量。
An open label study published in 2004 suggested that the use of Lopinavir / ritonavir in ribavirin reduced the risk of adverse clinical outcomes and viral load in SARS patients.
只是上述研究未进行随机化，无同期对照组，并且联用了糖皮质激素和利巴韦林，因此难以评估洛匹那韦 / 利托那韦的作用。
However, these studies were not randomized, no control group was available, and the combination of glucocorticoid and ribavirin made it difficult to assess the role of Lopinavir / ritonavir.
在体外试验和动物模型中，洛匹那韦对中东呼吸系统综合征冠状病毒（MERS-CoV）均有活性，并且有病例报告指出洛匹那韦 / 利托那韦与利巴韦林和干扰素联用可清除病毒，使患者存活。
In in vitro trials and animal models, Lopinavir is active in the Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and cases have been reported in which Lopinavir / Ritonavir, together with ribavirin and interferon, are used to remove viruses and keep patients alive.
鉴于上述背景，研究人员于 1 月 23 日在中国临床试验注册中心注册了《一项评价洛匹那韦 / 利托那韦治疗 2019 新型冠状病毒 (COVID-19)感染住院患者的疗效和安全性随机、开放、对照的研究》。
In view of the above background, the researchers registered a randomized, open and controlled study to evaluate the efficacy and safety of Lopinavir / Ritonavir in patients hospitalized with 2019 new coronavirus (COVID-19) infection on 23 January.
其实注册时间点已经是入组第 1 例患者之后，第一例患者于 1 月 18 日正式随机入组。
In fact, the time of registration was the first patient in the group, the first patients on January 18 formally randomly assigned to the group.
曹彬解释说，1 月 9 日完成试验立项后，原计划在美国 ClinicalTrials.gov 注册，但该网站以 “新冠病毒感染是地方性疾病” 为由拒绝了其注册。
After completing the trial on January 9, Cao explained, he had planned to register with Clinton Trials.gov in the United States, but the site refused to register him on the grounds that the New Crown Virus infection was endemic.
曹彬在一次直播节目中介绍过详细过程：在启动 RCT 研究之前，我们大概观察了 20 多例，这时候，有的医生反映这个药有效！但这只是个案，也就是仅仅只有一二十例。
Cao Bin in a live program described the detailed process: before we started the RCT study, we probably observed more than 20 cases, at this time, some doctors reported that the medicine is effective! But this is only an isolated case, that is, only a dozen or so cases.
后面大家也知道了洛匹拉韦 / 利托那韦的故事了，曾经一度被宣传成“神药”，但这是我们 RCT 启动以后的事情。
The story of Lopylavi / Litonavir, once touted as a "miracle drug," is something that has happened since the start of our RCT.
在早期，即使是我们一开始观察了 20 多例，部分大夫说有效的时候，我们都没敢讲“这个药可能是有效的”。
In the early days, even when we first looked at more than 20 cases, and some doctors said it worked, we didn't dare to say "this medicine may be effective."
我们仍非常严格地、耐心地启动了 RCT 的研究，我们首例病人入组是 1 月 18 日，从 1 月 9 日通过伦理委员会，到 1 月 18 日这一个星期左右，我们陆陆续续地观察了 20 多例病人，但是没有启动随机研究。
We have begun the RCT study with great rigour and patience, our first patient joining the group on January 18, passing the ethics committee on January 9, and continuing our observation of more than 20 patients a week or so before January 18, but no randomized study was initiated.
我们正式启动随机研究是在 2020 年 1 月 18 日，这就是我们洛匹拉韦 / 利托那韦临床研究的一个起点。
We officially launched the randomized study on January 18, 2020, a starting point for our clinical study in Lopilavir / Ritonavir.
这里提到的被宣传成 “神药” 的故事，正是北京大学第一医院呼吸和危重症医学科主任王广发的案例。
The "miracle drug" story mentioned here is the case of Wang Guangfa, director of respiratory and critical medicine at Peking University Hospital No. 1.
据王本人称，服用洛匹那韦 / 利托那韦后只用了 1 天的时间，其体温就降下来了。
According to Wang himself, it took only one day for Lopinavir / Ritonavir to get his temperature down.
“磨刀不误砍柴工”曹彬在微信公众号 “NEJM 医学前沿” 中呼吁磨刀不误砍柴工，与其开展单臂观察性研究获得不确切的结果，浪费研究者的精力和宝贵的受试者资源，不如开展随机对照临床试验探明几种药物的疗效和安全性，以图中国乃至世界在今后应对新发突发呼吸道传染病时更为从容。
Instead of carrying out one-arm observational studies that yield inaccurate results and waste researchers' energy and valuable subjects' resources, Cao Bin, a woodcutter, should conduct randomized controlled clinical trials to find out the efficacy and safety of several drugs, so as to make it easier for China and the world to deal with new respiratory infectious diseases.
在新发突发呼吸道传染病，快速明确有效治疗药物有诸多困难。
In the new outbreak of respiratory tract infectious diseases, rapid, clear and effective treatment of drugs have many difficulties.
曹彬说，2003 年 SARS 首先在中国暴发，但“由于当时条件和科研攻关能力有限，我们错失了对冠状病毒治疗药物的探索”。
"SARS first broke out in China in 2003, but" we missed the search for drugs to treat coronavirus because of the limited conditions and scientific research capabilities available at the time, "Cao said.
他认为，面对新发突发呼吸道传染病，有效治疗措施的探索时间窗极为狭窄，需要集中最宝贵的资源优先评价几种具有充分潜力的药物。
In his view, the exploration window for effective treatment measures in the face of new outbreaks of respiratory infectious diseases is extremely narrow, and priority needs to be given to the evaluation of several drugs with full potential, concentrating the most valuable resources.
中国香港学者的洛匹那韦 / 利托那韦研究并未得出明确结论，而沙特阿拉伯 MERS 感染患者中的研究中，启动试验较晚，目前临床试验仍未招募完成，错失了证明洛匹那韦 / 利托那韦疗效和安全性的机会。
The Lopinavir / Ritonavir study by scholars in Hong Kong, China, did not reach a definitive conclusion, and the late initiation of trials in studies with MERS infections in Saudi Arabia, where clinical trials have not yet been completed, missed an opportunity to demonstrate the efficacy and safety of Lopinavir / ritonavir.
正是因为此前连续错失两次验证此药的机会，间接导致此次新冠疫情期间无确切抗病毒药物的窘境。
Precisely because of two missed opportunities to validate the drug, there was no definitive antiviral drug during the new outbreak.
曹彬说，这次武汉的研究结果不但相对清晰明确了洛匹那韦 / 利托那韦对重症新冠肺炎有一定临床获益，而且为今后探索有效抗病毒药物积累了宝贵的经验。
Cao said the Wuhan study not only clearly identified the relative clinical benefits of Lopinavir / Ritonavir for severe new crown pneumonia, but also for the future exploration of effective antiviral drugs accumulated valuable experience.
这次研究中并未使用干扰素。
Interferon was not used in this study.
曹彬在上述直播节目中介绍说，在随机入组前了解 20 多例时发现，吸入干扰素的话会大大增加隔离病区护士的工作量，产生气溶胶的风险会增多，此外，一些观察病人在吸入干扰素后气道反应比较大，出现了气道刺激的不良反应。
Cao Bin in the above-mentioned live program said that in more than 20 cases before randomly assigned to the group, the inhalation of interferon will greatly increase the workload of nurses in isolated areas and increase the risk of aerosol production. In addition, some patients observed after inhalation of interferon airway reaction, there are adverse effects of airway stimulation.
虽然此次研究没有做到安慰剂对照，但曹彬说，负责药品临床试验管理规范 (GCP) 在进行临床终点评价时，是无法区分洛匹那韦 / 利托那韦组和对照组的。
Although the study was not placebo-controlled, Cao said the GCP, which regulates clinical trials of drugs, was unable to distinguish between the Lopinavir / Ritonavir group and the control group.
曹彬说，这次研究做到了严格的随机。
The study was strictly random, Cao said.
两组的中位年龄都是 58 岁，性别比、基础疾病、入组当时的实验室检查，还有这些患者的病情严重程度，以及这些病人入组之后所使用的这些干预药物（包括激素），也都匹配。
The median age of both groups was 58 years, and the sex ratio, basic diseases, laboratory tests at the time of admission to the group, and the severity of the patients' conditions, as well as the interventions (including hormones) used by these patients after their admission to the group.
在这样的一个背景下，这两组唯一的区别就是其中一组多了“洛匹拉韦 / 利托那韦”，“我们就可以比较有自信地去进行比较了”。
In such a context, the only difference between the two groups is that they are more "Lopilavir / Ritonavir" and "we can compare with each other with more confidence."
本研究最初设定的总样本量为 160 例患者，研究人员判定本试验的统计学功效不足，随后决定继续纳入患者。
The study initially set the total sample size at 160 patients, but the researchers judged the test statistically ineffective and then decided to continue to include patients.
谈到此次研究的局限性，论文指出，本试验未采用盲法，那么医生和患者在知晓分组情况后可能影响临床决策，进而可能影响研究采用的 7 分等级量表。
Referring to the limitation of this study, the paper points out that blind method is not used in this experiment, then doctors and patients may influence clinical decision-making after knowing about the grouping, which may affect the 7-scale scale used in the study.
至于为何没有采用双盲，张定宇在接受 DeepTech 采访时称，当时手头只有洛匹那韦 / 利托那韦，为了推进研究，来不及做安慰剂。
As to why double-blindness was not used, Zhang told DeepTech he had only Lopinavir / Ritonavir at hand, too late to act as a placebo to advance the study.
-End-。
- End-.
发送到看一看 。
Send it to see.
医学顶刊首发新冠临床试验结果：中国研究证实克力芝收效甚微，不能降低重症死亡率。
Results of new crown clinical trial of top issue of medical science: Chinese research has proved that Kaletra has little effect and can not reduce severe mortality.
查看更多相关内容。
See more for more information.
查看更多相关内容。
See more for more information.
以上推荐为优质及原创文章。
Above recommendations for quality and original articles.
长按识别前往小程序。
Long press identify to go to the applet.
var _ori_article_type = "科技互联网";。
var _ ori _ article _ type = & quot; & T & T & T;;
var nickname = "DeepTech深科技";。
var nickname = & quot; DeepTech & quot;;
var msg_title = "医学顶刊首发新冠临床试验结果：中国研究证实克力芝收效甚微，不能降低重症死亡率";。
var msg _ title = & quot; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45;
var msg_desc = "3 月 19 日，《新英格兰医学杂志》（NEJM）在线发表中国团队关于抗艾滋药物洛匹那韦 / 利托那韦研究称";。
var msg _ desc = & quot; & quot; & quot; & quot; & quot; & # 160; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45;
var title ="DeepTech深科技";。
var title = & quot; DeepTech & quot;;
